Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & CEO | 676.54k | -- | 1973 |
| Ms. Christine Mikail Cvijic J.D. | President, CFO & Corporate Secretary | 623.29k | -- | 1978 |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer | 478.81k | -- | 1970 |
| Ms. Donna M. Cochener-Metcalfe J.D. | Senior VP & General Counsel | -- | -- | 1975 |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical & Translational Research | -- | -- | -- |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | -- | -- | -- |
| Mr. Ricardo Jimenez | Senior Vice President of Technical Operations | -- | -- | -- |
| Mr. Arvind Sreedharan | Senior Vice President of Business Operations | -- | -- | -- |
| Dr. Julie Jordan M.D. | Chief Medical Officer | -- | -- | 1972 |
Neurogene Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 107
Description
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
Corporate Governance
Upcoming Events
May 8, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Neurogene Inc. Earnings Date
Recent Events
March 24, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
December 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission